RECEIVED : **CENTRAL FAX CENTER** AUG 1 0 2006

Facsimile Cover Sheet For Transmission to the United States Patent and Trademark Office

):	U.S. Patent and Trademark Office		
	Fax. No.	(571) 273-8300	
	Application No.	10/696,464	
	Filing Date:	October 29, 2003	
	Confirmation No.:	5983	
	Examiner:	Sarah E. Perlinger	
	Art Unit:	1625	
	Attorney Docket No.	P-142-US1	
	Theravance, Inc.		
From:	Attorney:	Jeffrey A. Hagenah	
	Reg. No. :	35,175	
	Customer No.:	27038	
	Customer 140	901 Gateway Boulevard	
	Address:	South San Francisco, California 94080	
	Telephone No.:	(650) 808-6406	
	Fax. No.:	(650) 808-6078	
Date:	August 10_, 2006		
No. of Pages :	31 (including this page)		
	Certificate of Fa	acsimile Transmission	
I hereby cert Number (571)	ify that this corresponde	nce is being transmitted via Facsimile States Patent and Trademark Office, on icated above.	
Signature :	SA AS	A. O	
	La Hachnah	, Reg. No. 35,175	
Printed Name:	Jenrey M. Hayenan	, 1 tog. 1 to 1	

The information contained in this facsimile is intended solely for use by the United States Patent and Trademark Office. If this facsimile is received in error, please notify the sender and destroy the facsimile.

PTO/SB/21 (09-04)

Approved for use through 07/31/2008. OMB 0851/0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

		Application Number	10/696,464 RECEIVED
TRANSMITTAL FORM		Filing Date	October 29, 2003 CENTRAL FAX CE
		First Named Inventor	Mainifier of all
	ļ	Art Unit	1625 AUG 1 0 200
		Examiner Name	Sarah E. Perlinger
(to be used for all correspondence after Initial filling)		Attorney Docket Number	P-142-US1
al Number of Pages in This Submission			
		OSURES (check all that appl)	After Allowance Communication to TC
Fee Transmittal Form	Drawing(s)	Appeal Communication to Board
Fee Attached	Licensing	g-related Papers	of Appeals and Interferences
Amendment / Reply (29 pages)	Petition		Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
After Final	Petition to Convert to a Provisional Application		Proprietary Information
Affidavits/declaration(s)	Power of Attorney, Revocation Change of Correspondence Address		Status Letter
	Terminal Disclaimer		Other Enclosure(s) (please identify below):
Extension of Time Request	le send		Facsimile Cover Page (1 page)
Express Abandonment Request	Request for Refund CD, Number of CD(s)		
1 0 0 0 1		andscape Table on CD	
Information Disclosure distant			
Certified Copy of Priority Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts	No fees are believed to be due for subn the Commissioner is authorized to cha overpayment, to Deposit Account No. 5		mission of this paper. However, if a fee is due, irge any such fee, or to credit any 50-0344 (in the name of Theravance, Inc.)
under 37 CFR1.52 or 1.53			
SIC	GNATURE C	F APPLICANT, ATTORNE	Y, OR AGENT
Firm Theraval		non Inc	
Firm	11101010	nce, inc.	
Firm Signature	134	A. Mey	
	M	A. A.	
Signature	Jeffrey A	Hagenah 10, 2006	eg. 35,175 o. 35,175
Signature Printed Name Date	Jeffrey A	Hagenah 10, 2006 RANSMISSIO	eg. 35,175 o. 35,175
Signature Printed Name Date I hereby certify that this correspond	Jeffrey A August CERTIF dence is being	Hagenah 10, 2006 RANSMISSIO g facsimile transmitted to the nail in an envelope addresse	eg. 35,175 o. 35,175
Signature Printed Name Date	Jeffrey A August CERTIF dence is being	Hagenah 10, 2006 RANSMISSIO g facsimile transmitted to the nail in an envelope addresse	eg. 35,175 n/MAILING

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the gathering, preparing, and submitting the complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Petent and amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

CENTRAL FAX CENTER

AUG 1 0 2006

Certificate of Facsimile Transmission

I hereby certify that this correspondence is being transmitted on the date shown below via facsimile to the Commissioner for Patents, United States Patent and Trademark Office at the facsimile number indicated. Facsimile Number: (571) 273-8300 Dated: August 10, 2006

PATENT Attorney Docket No. P-142-US1 Customer No. 27038

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of)
MAMMEN et al.) Confirmation No. 5983
Application No.: 10/696,464) Group Art Unit: 1625
Filed: October 29, 2003) Examiner: Sarah E. Perlinger)
For: SUBSTITUTED 4-AMINO-1- (PYRIDYLMETHYL)PIPERIDINE AND RELATED COMPOUNDS)

REPLY AND AMENDMENT PURSUANT TO 37 C.F.R. §1.111

Mail Stop Amendment

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

INTRODUCTORY REMARKS I.

This reply is being filed in response to the Office Action mailed on May 31, 2006, for the above-identified patent application. The Office Action set a three-month period for response and therefore, this reply is due on or before August 31, 2006. In response to the Office Action, entry of the following amendments and consideration of the following remarks is respectfully requested.

Amendments to the Claims begin on page 2 of this paper.

Remarks begin on page 27 of this paper.